Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population.

and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.

Inclusion Criteria:

• Documented diagnosis of relapsed or refractory multiple myeloma (MM).
• Age > 18 years at the time of signing the informed consent form
• Stable renal function

Exclusion Criteria:

• Documented amyloidosis

• Any prior use of Revlimid ®

• Any contraindication to Revlimid ® and especially:

• Lack of acceptable method of birth control for female of childbearing potential (FCPB)

  • Men who don't agree to use condom during the study and 4 weeks after the last study drug intake if their partner is a FCPB.
  • Pregnant or breast feeding women